磁共振与三维经直肠超声分割的相对体积差异对融合磁共振靶向前列腺穿刺活检中临床显著前列腺癌检出率的影响
研究连续纳入2012年2月至2021年7月因临床怀疑前列腺癌行磁共振靶向前列腺穿刺活检的成年男性,评估三维经直肠超声与磁共振分割的相对体积差异对靶向穿刺活检临床显著前列腺癌(ISUP≥2)检出的影响。结果显示,磁共振体积相对分割体积差异>10%与临床显著前列腺癌检出率降低相关(比值比=0.74,95%CI 0.55-0.98,P=0.038),该差异可作为三维经直肠超声分割的每操作质量指标。
要点
- 磁共振与经直肠超声分割相对体积差异>10%与靶向穿刺临床显著前列腺癌检出率降低相关。
- 临床显著前列腺癌患者的中位相对分割体积差异显著低于ISUP 0-1患者。
- 相对分割体积差异可作为三维经直肠超声分割的每操作质量指标。
核心结论
- 磁共振分割体积的相对分割体积差异>10%与靶向穿刺活检核心中临床显著前列腺癌检出率降低相关,该差异可作为三维经直肠超声分割的每操作质量指标。
研究设计与样本
- 连续纳入2012年2月至2021年7月因临床怀疑前列腺癌行磁共振靶向前列腺穿刺活检的所有成年男性,所有患者均使用Koelis设备行融合磁共振靶向前列腺穿刺活检。
主要发现
- 共1721例患者接受靶向前列腺穿刺活检,合计5593个靶向穿刺核心。
- 临床显著前列腺癌患者的中位相对分割体积差异显著低于ISUP 0-1患者:6.7%(四分位距-2.7至13.6)对8.0%(四分位距3.3至16.4),P<0.01。
- 多因素回归分析显示,磁共振体积的相对分割体积差异>10%与临床显著前列腺癌检出率降低相关(比值比=0.74,95%CI 0.55-0.98,P=0.038)。
关键数值与推荐
- 临床显著前列腺癌定义为国际泌尿病理学会(ISUP)≥2。
- 相对分割体积差异计算公式为(磁共振体积-经直肠超声体积)/磁共振体积。
- 磁共振体积的相对分割体积差异>10%对应的临床显著前列腺癌检出比值比=0.74(95%CI 0.55-0.98,P=0.038)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Segmentation of three-dimensional (3D) transrectal ultrasound (TRUS) images is known to be challenging, and the clinician often lacks a reliable and easy-to-use indicator to assess its accuracy during the fusion magnetic resonance imaging (MRI)-targeted prostate biopsy procedure. OBJECTIVE: To assess the effect of the relative volume difference between 3D-TRUS and MRI segmentation on the outcome of a targeted biopsy. DESIGN, SETTING, AND PARTICIPANTS: All adult males who underwent an MRI-targeted prostate biopsy for clinically suspected prostate cancer between February 2012 and July 2021 were consecutively included. INTERVENTION: All patients underwent a fusion MRI-targeted prostate biopsy with a Koelis device. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Three-dimensional TRUS and MRI prostate volumes were calculated using 3D prostate models issued from the segmentations. The primary outcome was the relative segmentation volume difference (SVD) between transrectal ultrasound and MRI divided by the MRI volume (SVD = MRI volume - TRUS volume/MRI volume) and its correlation with clinically significant prostate cancer (eg, International Society of Urological Pathology [ISUP] ≥2) positiveness on targeted biopsy cores. RESULTS AND LIMITATIONS: Overall, 1721 patients underwent a targeted biopsy resulting in a total of 5593 targeted cores. The median relative SVD was significantly lower in patients diagnosed with clinically significant prostate cancer than in those with ISUP 0-1: (6.7% [interquartile range {IQR} -2.7, 13.6] vs 8.0% [IQR 3.3, 16.4], p < 0.01). A multivariate regression analysis showed that a relative SVD of >10% of the MRI volume was associated with a lower detection rate of clinically significant prostate cancer (odds ratio = 0.74 [95% confidence interval: 0.55-0.98]; p = 0.038). CONCLUSIONS: A relative SVD of >10% of the MRI segmented volume was associated with a lower detection rate of clinically significant prostate cancer on targeted biopsy cores. The relative SVD can be used as a per-procedure quality indicator of 3D-TRUS segmentation. PATIENT SUMMARY: A discrepancy of ≥10% between segmented magnetic resonance imaging and transrectal ultrasound volume is associated with a reduced ability to detect significant prostate cancer on targeted biopsy cores.
引用
- Lenfant L, Beitone C, Troccaz J, et al. Impact of Relative Volume Difference Between Magnetic Resonance Imaging and Three-dimensional Transrectal Ultrasound Segmentation on Clinically Significant Prostate Cancer Detection in Fusion Magnetic Resonance Imaging-targeted Biopsy. Eur Urol Oncol. 2023. PMID: 37599199. doi:10.1016/j.euo.2023.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。